TickerFacts.

Prokidney Corp. (PROK): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$1.01B
As of 2025-12-31
-$883.53M
As of 2026-06-30
$26.92M2020-12-31: $9.86M2021-12-31: $26.92M2022-12-31: -$1.10B2023-12-31: -$1.10B2024-12-31: -$994.95M2025-12-31: -$1.01B-$1.01B
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$1.01Bn/m2026-03-18, Balance as of period end
2024-12-31-$994.95Mn/m2026-03-18, Balance as of period end
2023-12-31-$1.10Bn/m2026-03-18, Balance as of period end
2022-12-31-$1.10Bn/m2025-03-17, Balance as of period end
2021-12-31$26.92M+172.9%2024-03-22, Balance as of period end
2020-12-31$9.86Mn/a2023-03-28, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Prokidney Corp. (PROK)2025-12-31-$1.01Bn/m
ImageneBio, Inc. (IMA)2025-12-31$133.14Mn/m
Pluri Inc. (PLUR)2026-06-30-$23.04Mn/m
Inhibrx Biosciences, Inc. (INBX)2025-12-31$7.99M-94.0%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$8.10M-18.8%
Cardiff Oncology, Inc. (CRDF)2025-12-31$45.39M-45.3%
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$32.19Mn/m
Humacyte, Inc. (HUMA)2025-12-31$3.11Mn/m
Aligos Therapeutics, Inc. (ALGS)2025-12-31$53.55Mn/m

Compare PROK, IMA, PLUR, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗